A Swedish-led study validated a self-administered digital cognitive test (BioCog) in primary care, showing it can accurately detect objective cognitive impairment before blood biomarkers are applied. When paired with a targeted amyloid blood test, this stepwise pathway outperformed standard assessments for diagnosing clinical Alzheimer’s disease.